Max Planck Innovation Launches Early-Stage Fund
This article was originally published in Start Up
Frustrated by the continued lack of early-stage VC funding for projects emerging from its laboratories, Max Planck Innovations GMBH is launching its own VC fund, DDC Ventures. The fund is just one component of an ambitious tech transfer initiative dubbed the "drug development center", which kicked off last year with the creation of a Lead Discovery Center in Dortmund, Germany.
You may also be interested in...
University College London spin-out Pentraxin's February 2009 tie-up with GlaxoSmithKline in amyloidosis showed GSK's willingness to invest in risky, early-stage research. Weeks later, Pentraxin announced promising clinical data with a related program in Alzheimer's, raising the possibility that this alliance may yet expand beyond a specialist niche.
A handful of early-stage VCs think they can generate better returns building and selling individual products, rather than companies.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.